250 related articles for article (PubMed ID: 29642773)
1. DCE-MRI-Derived Volume Transfer Constant (K
Ye ZM; Dai SJ; Yan FQ; Wang L; Fang J; Fu ZF; Wang YZ
Technol Cancer Res Treat; 2018 Jan; 17():1533034618765254. PubMed ID: 29642773
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of short- and long-term efficacy of chemoradiotherapy for advanced cervical cancer using HSP70 protein combined with multimodal MRI.
Qi YX; Liu K; Yin J; Li L
J Cell Biochem; 2018 Apr; 119(4):3017-3029. PubMed ID: 29023986
[TBL] [Abstract][Full Text] [Related]
4. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
5. Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy.
Onal C; Erbay G; Guler OC
J Magn Reson Imaging; 2016 Oct; 44(4):1010-9. PubMed ID: 26919800
[TBL] [Abstract][Full Text] [Related]
6. The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker for disease recurrence.
Nakamura K; Joja I; Nagasaka T; Fukushima C; Kusumoto T; Seki N; Hongo A; Kodama J; Hiramatsu Y
Gynecol Oncol; 2012 Dec; 127(3):478-83. PubMed ID: 22892362
[TBL] [Abstract][Full Text] [Related]
7. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.
Heethuis SE; Goense L; van Rossum PSN; Borggreve AS; Mook S; Voncken FEM; Bartels-Rutten A; Aleman BMP; van Hillegersberg R; Ruurda JP; Meijer GJ; Lagendijk JJW; van Lier ALHMW
Acta Oncol; 2018 Sep; 57(9):1201-1208. PubMed ID: 29781342
[TBL] [Abstract][Full Text] [Related]
8. Prediction of early response to concurrent chemoradiotherapy in cervical cancer: Value of multi-parameter MRI combined with clinical prognostic factors.
Zheng X; Guo W; Dong J; Qian L
Magn Reson Imaging; 2020 Oct; 72():159-166. PubMed ID: 32621877
[TBL] [Abstract][Full Text] [Related]
9. Optimization of b-values in diffusion-weighted imaging for esophageal cancer: Measuring the longitudinal length of gross tumor volume and evaluating chemoradiotherapeutic efficacy.
Liu G; Yang Z; Li T; Yang L; Zheng X; Cai L
J Cancer Res Ther; 2017; 13(5):748-755. PubMed ID: 29237898
[TBL] [Abstract][Full Text] [Related]
10. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
Wang L; Liu L; Han C; Liu S; Tian H; Li Z; Ren X; Shi G; Wang Q; Wang G
Radiother Oncol; 2016 Nov; 121(2):246-251. PubMed ID: 27838148
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Ng SH; Lin CY; Chan SC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Huang SF; Lin YC; Wang JJ
PLoS One; 2013; 8(8):e72230. PubMed ID: 23951300
[TBL] [Abstract][Full Text] [Related]
12. Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics.
Gollub MJ; Hotker AM; Woo KM; Mazaheri Y; Gonen M
Abdom Radiol (NY); 2018 Jul; 43(7):1575-1582. PubMed ID: 29159523
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of diffusion weighted and dynamic contrast-enhanced MRI in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy.
Garbajs M; Strojan P; Surlan-Popovic K
Radiol Oncol; 2019 Mar; 53(1):39-48. PubMed ID: 30840595
[TBL] [Abstract][Full Text] [Related]
14. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer.
Qin F; Pang H; Ma J; Zhao M; Jiang X; Tong R; Yu T; Luo Y; Dong Y
Eur J Radiol; 2021 Aug; 141():109787. PubMed ID: 34051683
[TBL] [Abstract][Full Text] [Related]
15. Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma.
Liu C; Sun R; Wang J; Ning F; Wang Z; Luo J; Chen S; Yuan S
Biomed Res Int; 2020; 2020():2576563. PubMed ID: 32626736
[TBL] [Abstract][Full Text] [Related]
16. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.
Fasmer KE; Bjørnerud A; Ytre-Hauge S; Grüner R; Tangen IL; Werner HM; Bjørge L; Salvesen ØO; Trovik J; Krakstad C; Haldorsen IS
Acta Radiol; 2018 Aug; 59(8):1010-1017. PubMed ID: 29137496
[TBL] [Abstract][Full Text] [Related]
17. Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:: Association with Prognostic Factors in Breast Cancer.
Lee HS; Kim SH; Kang BJ; Baek JE; Song BJ
Acad Radiol; 2016 Apr; 23(4):446-56. PubMed ID: 26852247
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted imaging in evaluating the efficacy of concurrent chemoradiotherapy in the treatment of non-small cell lung cancer.
Xu HD; Zhang YQ; Shen WY; Mao ZC
Tumori; 2018 Jun; 104(3):188-195. PubMed ID: 28362059
[TBL] [Abstract][Full Text] [Related]
20. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
